feed,title,long_url,short_url
Benzinga,LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma,https://www.benzinga.com/pressreleases/21/02/a19658409/lenvima-lenvatinib-plus-keytruda-pembrolizumab-demonstrated-superior-progression-free-survival-pfs,https://j.mp/3ddAjZX
